Miniaturized screening technologies for drug discovery.
Biochem Soc Trans
; 30(4): 802-6, 2002 Aug.
Article
em En
| MEDLINE
| ID: mdl-12196202
ABSTRACT
Adaptive Profiling (APL) and other biochip companies aim to harness the power of microsystems technology together with advances in chemistry and molecular biology, to become service and technology providers to organizations involved in pharmaceutical research and development. By supplying a unique range of decision-making tools that aid an earlier identification of qualified drug candidates for clinical development, the company should gain a significant share of the 10 billion US dollar biological screening, bioavailability and toxicity assessment market.
Buscar no Google
Temas:
ECOS
/
Estado_mercado_regulacao
Bases de dados:
MEDLINE
Assunto principal:
Indústria Farmacêutica
/
Avaliação Pré-Clínica de Medicamentos
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Limite:
Animals
Idioma:
En
Revista:
Biochem Soc Trans
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
Reino Unido